Science Translational Medicine
03 May 2017 Vol 9, Issue 388
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
By Qing Zhu, Jason S. McLellan, Nicole L. Kallewaard, Nancy D. Ulbrandt, Susan Palaszynski, Jing Zhang, Brian Moldt, Anis Khan, Catherine Svabek, Josephine M. McAuliffe, Daniel Wrapp, Nita K. Patel, Kimberly E. Cook, Bettina W. M. Richter, Patricia C. Ryan, Andy Q. Yuan, JoAnn A. Suzich
Science Translational Medicine03 May 2017 Full Access
Development of a highly potent anti-RSV monoclonal antibody with extended half-life intended to be used as RSV prophylaxis for all infants.
The common respiratory syncytial virus (RSV) can progress to a very dangerous lower respiratory infection in some infants. A protective monoclonal antibody is available but is not recommended for general use. Zhu et al. describe the selection and optimization of a human monoclonal antibody able to neutralize a wide array of RSV A and B viruses and protect cotton rats at lower doses than the currently approved antibody. The antibody was optimized to persist in circulation, and data indicate that infants could be given a single dose and be protected for the entirety of the RSV season. If administered widely, this antibody could potentially prevent the hospitalization of thousands of children each year.